title: [Electrophysiological correlates of efficacy of nootropic drugs in the treatment of consequences of traumatic brain injury in adolescents].
abstract: To assess objectively a dynamics of brain functional state, EEG spectral power and peak latency of the P300 component of cognitive auditory evoked potentials have been analyzed in adolescents during the course of nootropic therapy of residual asthenic consequences of traumatic brain injury (ICD-10 F07.2). The study included 76 adolescents, aged 12-18 years, who have undergone severe closed head trauma with brain commotion 1/2--5 years ago. Patients have been divided into 3 groups treated during one month with cerebrolysin, piracetam or magne-B6, respectively. After the end of the nootropic therapy, 77% of patients treated with cerebrolysin as well as 50% of patients treated with piracetam and magne-B6 have demonstrated the positive dynamics of their brain functional state that manifested itself in the appearance of occipital EEG alpha rhythm or in the increase of its spectral power; in the normalization of alpha rhythm frequency; in the decrease in the spectral power of slow wave (theta and delta) EEG activity, in the amount (up to the disappearance) of paroxysmal EEG activity, in the EEG response to hyperventilation and in the shortening of the P300 peak latency. Such positive changes of neurophysiological parameters have been associated with the improvement of clinical conditions of patients and correlated significantly with the dynamics of psychometric scores of attention and memory.
authors.forename: E V
authors.initials: EV
authors.lastname: Iznak
authors.forename: A F
authors.initials: AF
authors.lastname: Iznak
authors.forename: E A
authors.initials: EA
authors.lastname: Pankratova
authors.forename: N N
authors.initials: NN
authors.lastname: Zavadenko
authors.forename: L S
authors.initials: LS
authors.lastname: Guzilova
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Guzilova
mesh_terms: D000293:Adolescent; D000596:Amino Acids / Q000627:therapeutic use*; D001247:Asthenia / Q000209:etiology / Q000517:prevention & control*; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D002648:Child; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D008297:Male; D018697:Nootropic Agents / Q000627:therapeutic use*; D010889:Piracetam / Q000627:therapeutic use*; D016896:Treatment Outcome; D025101:Vitamin B 6 / Q000627:therapeutic use
chemical_list: D000596:Amino Acids; D018697:Nootropic Agents; C006952:cerebrolysin; D025101:Vitamin B 6; D008274:Magnesium; D010889:Piracetam